PUT PATIENTS FIRST
WITH OXLUMO® (lumasiran),
THE FIRST APPROVED THERAPY
FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)1-3

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) levels in children and adults. Oxlumo acts at the liver, the site of oxalate production. Overproduction of oxalate is the primary cause of disease manifestation in PH1.1

Tell Me About OXLUMO Tell Me About PH1

Grace*
Person with PH1
*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
Image
Couple walking

Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

Treatment with OXLUMO led to powerful reduction in 24-hour urinary oxalate in patients with PH11

Treatment with OXLUMO resulted in a 53% reduction in 24-hour UOx excretion from baseline to month 6 (primary endpoint for ILLUMINATE-A) for OXLUMO compared to placebo in a double-blind clinical trial of 39 patients ≥6 years with eGFR ≥30 mL/min/1.73 m.1,4,5,†

Least squares mean reduction averaged over months 3 through 6, corrected for BSA (OXLUMO, 65%; placebo, 12%); 95% CI: 45%, 62%; P<0.0001 vs placebo.

Show Me the Data

The dosing regimen for OXLUMO led to a rapid reduction in 24-hr UOx within 2 weeks, which was sustained through 12 months1,4,†

OXLUMO is a subcutaneous injection dosed by weight.

Show Me the Dosing Regimens

In ILLUMINATE A: 24 hour urinary demonstrated reduction in 24 hr UX excretion from baseline to month 6 for OXLUMO compared to PBO.

Image
Person With PH1 Disease
Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Image
'

There’s more to learn about OXLUMO

When you sign up, we will keep you informed with updates and resources.

Sign Me Up

Image
Alnylam Assist™ Logo

Dedicated support in your patients' journey with Alnylam Assist™

Alnylam Assist™ is committed to providing personalized support throughout treatment with OXLUMO. The program includes patient services in key areas, including understanding insurance benefits and financial assistance options, helping ensure access to therapy, and providing PH1 disease education.

Let's Get Started

NEXT:

LEARN MORE ABOUT PH1: A DISEASE OF OXALATE OVERPRODUCTION4.7

 ABOUT
PH1

References: 1. OXLUMO (lumasiran) [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals. 2. Liebow A, Li X, Racie T, et al. J Am Soc Nephrol. 2017;28(2):494-503. 3. Hoppe B. Nat Rev Nephrol. 2012;8(8):467-475. 4. Saland J, Groothoff J, Frishberg Y, et al. Presented at: American Society of Nephrology; October 22-25, 2020. 5. ClinicalTrials.gov identifier: NCT03681184. Updated July 10, 2020. Accessed July 15, 2021. https://clinicaltrials.gov/ct2/show/NCT03681184

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common adverse reaction that occurred in patients treated with OXLUMO® (lumasiran) was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.